



## LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

**London and Oxford, UK, 09 July 2020:** Today, LGC announced the acquisition of The Native Antigen Company (NAC), one of the world's leading suppliers of high quality infectious disease antigens and antibodies.

NAC is a developer, manufacturer and supplier of critical reagents to the *in vitro* diagnostic (IVD), pharmaceutical and academic sectors. It offers a comprehensive portfolio of native and recombinant infectious disease antigens and related products including pathogen receptors, virus-like particles and antibodies for use in immunoassay applications, vaccine development and quality control solutions. NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to play an important role in supporting the global response to the COVID-19 pandemic.

The acquisition strengthens LGC's existing product offering to the IVD sector, which includes a range of quality assurance tools, immunoassay reagents and disease state plasma as well as probes and primers for molecular diagnostics.

**Michael Sweatt, Executive Vice President and General Manager, Clinical Diagnostics, LGC, said:** "NAC is a natural fit with our clinical diagnostics business and will enable us to provide an expanded portfolio of critical reagents to our customers. NAC's focus on infectious disease is highly complementary with our existing offer to this segment comprising controls, reference materials, MDx tools and other components. We are excited to welcome our new colleagues into our organisation."

"We are delighted to be joining LGC as an integral part of their fast growing clinical diagnostics business", **said Nick Roesen, COO of NAC,** "even more so, we are excited to join such a well-respected organisation that shares our purpose and mission, and that will support our diagnostic customers by providing even more world-leading products and services."

Formed in 2010, NAC is based in Oxford, UK and currently employs over 30 people. It maintains an ISO 9001 accreditation.

NAC's portfolio includes more than 60 viral and infectious disease products, with strengths in Dengue, Cytomegalovirus, Zika, Chikungunya and *Clostridium difficile* (*C. diff*).

**ENDS**

**Notes to Editors**



Dr Nick Roesen, COO of NAC

For a high-resolution image please contact Zyme Communications.

**For further information please contact:**

**LGC**

Guenaelle Holloway, Head of Corporate Communications

Email: [guenaelle.holloway@lgcgroup.com](mailto:guenaelle.holloway@lgcgroup.com)

Tel: +44 (0) 7720 497 997

**NAC (Zyme Communications)**

Lorna Cuddon, Managing Director

Email: [lorna.cuddon@zymecommunications.com](mailto:lorna.cuddon@zymecommunications.com)

Tel: +44 (0) 7811 996 942

*To opt-out from receiving press releases from Zyme Communications please e-mail [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#).*

**About LGC**

LGC is a global leader in the life science tools sector, providing mission critical components to customers across clinical diagnostics, pharmaceutical, research & government, food and other applied markets.

LGC provides a comprehensive range of specialty genomic analysis tools, measurement tools and supply chain assurance solutions, underpinned by leading analytical and measurement science capabilities. It holds a number of international roles, including the UK Government Chemist programme and serving as the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement.

LGC's scientific tools and solutions form an essential part of its customers' quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. Its 3,500 employees include internationally-recognised scientists who are experts in their field. Headquartered in London, LGC operates out of 19 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.

LGC was founded in 1842. It has been privately-owned since 1996 and has diversified through internal investment and acquisitions to be an international leader in its chosen markets. LGC is now owned by funds affiliated to Cinven, Astorg and ADIA.

For more information, please visit [www.lgcgroup.com](http://www.lgcgroup.com)

**About The Native Antigen Company** [thenativeantigencompany.com](http://thenativeantigencompany.com)

The Native Antigen Company is one of the world's leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke product development and custom manufacturing using its proprietary mammalian cell expression system.

The Native Antigen Company's team have decades of experience in the isolation and purification of native antigens and high-yield mammalian cell expression systems, ensuring conformity to native type. The Company's high-quality reagents have been widely adopted by leading pharmaceutical, in vitro diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.

The Native Antigen Company prides itself on an ethical and sustainable approach, exemplified by its use of 100% renewable energy and recycled packaging wherever possible, and building honest and transparent relationships with its customers and collaborators.

Founded in 2010, The Native Antigen Company is located in Oxford (UK) and has a global network of distributors.

Follow The Native Antigen Company on Twitter [@nativeantigen](https://twitter.com/nativeantigen) and LinkedIn [@The Native Antigen Company](https://www.linkedin.com/company/the-native-antigen-company)